Bionik Laboratories Corp.
BNKLOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$1248
P/E Ratio—
52W High$0.0001
52W Low$0.0001
Bionik Laboratories Corp. (BNKL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BNKL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2023Report Date: Jun 21, 2023EPS Actual
-$0.08
Revenue
$0.00B
Fiscal Period
Q2 FY2023
FY ends December
Report Date
Jun 21, 2023
After Market Close
BNKL reports quarterly as a OTC-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | Jun 19, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | Jun 19, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Jan 19, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 27, 2023 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Aug 25, 2023 | — | — | — | — | — | — |
| — Q2 FY2023 | Jun 21, 2023 | — | -$0.08 | — | $0.00B | — | — |
| — Q1 FY2023 | Feb 8, 2023 | — | -$0.15 | — | $0.00B | — | — |
| — Q4 FY2022 | Nov 9, 2022 | — | -$0.15 | — | $0.00B | — | — |
Q2 FY2024
Jun 19, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Jun 19, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Jan 19, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 27, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 25, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
Jun 21, 2023
EPS Actual
-$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Feb 8, 2023
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Nov 9, 2022
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2023 | Jun 21, 2023 | — | $0.60 | $0.61 | +1.67% |
| — Q1 FY2023 | Feb 8, 2023 | — | $0.62 | $0.62 | +0.00% |
| — Q4 FY2022 | Nov 9, 2022 | — | $0.30 | $0.30 | +0.00% |
| — Q3 FY2022 | Aug 10, 2022 | — | $0.60 | $0.60 | +0.00% |
| — Q2 FY2022 | Jun 9, 2022 | — | $1.00 | $1.00 | +0.00% |
| — Q1 FY2022 | Feb 9, 2022 | — | $0.90 | $0.90 | +0.00% |
| — Q4 FY2021 | Nov 10, 2021 | — | $2.00 | $2.00 | +0.00% |
Q2 FY2023+1.67%
Report Date
Jun 21, 2023
EPS Beat/Miss
—
Price Before
$0.60
Price After
$0.61
Q1 FY2023+0.00%
Report Date
Feb 8, 2023
EPS Beat/Miss
—
Price Before
$0.62
Price After
$0.62
Q4 FY2022+0.00%
Report Date
Nov 9, 2022
EPS Beat/Miss
—
Price Before
$0.30
Price After
$0.30
Q3 FY2022+0.00%
Report Date
Aug 10, 2022
EPS Beat/Miss
—
Price Before
$0.60
Price After
$0.60
Q2 FY2022+0.00%
Report Date
Jun 9, 2022
EPS Beat/Miss
—
Price Before
$1.00
Price After
$1.00
Q1 FY2022+0.00%
Report Date
Feb 9, 2022
EPS Beat/Miss
—
Price Before
$0.90
Price After
$0.90
Q4 FY2021+0.00%
Report Date
Nov 10, 2021
EPS Beat/Miss
—
Price Before
$2.00
Price After
$2.00
Beat Rate0 / 7 quarters
Largest Move+1.67% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BNKL ends December
Bionik Laboratories Corp. (BNKL) most recently reported earnings on June 21, 2023 for Q2 FY2023, posting EPS of $-0.08 (in line with the analyst consensus of —). The next BNKL earnings date is expected around September 1, 2026.
Each quarter, investors track BNKL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BNKL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BNKL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BNKL earnings · 4 questionsBionik Laboratories Corp.'s next earnings report is expected around September 1, 2026. BNKL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BNKL historically reports after market close (AMC).
BNKL earnings datewhen is BNKL earningsBNKL next earnings datewhen does BNKL report earningsBNKL earnings calendar
▸ Source: FMP · Bionik Laboratories Corp. SEC filings · US GAAP · Bionik Laboratories Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026